Abstract:Aim To prepare a solid dispersion of cisapride with hydroxypropylmethyl cellulose (HPMC E5 LV) as carrier for the purpose of accelerating the in vitro drug release by means of improving the solubility of the model drug. Methods Alcohol and simulated gastric fluid (SGF) were used to dissolve cisapride and HPMC in order to make the model drug dispersed homogeneously in the carrier. The HPMC-cisapride solid dispersion was then obtained by conventional solvent evaporation method. Powder X-ray diffraction (XRD) was used to measure the diffraction peaks of pure carrier, pure cisapride, physical mixture of HPMC with cisapride (4∶1), and HPMC-cisapride solid dispersion (4∶1) to confirm the crystal existence. The solubility of pure drug and HPMC-cisapride solid dispersion was measured with water, SGF and simulated intestinal fluid (SIF). The in vitro drug releases of the sustained release tablet prepared with pure cisapride or HPMC-cisapride solid dispersion were investigated with water and SGF as media, respectively. Results No diffraction peaks were found by X-ray diffraction in the HPMC-cisapride solid dispersion (4∶1), indicating that the drug existed in an amorphous form at that drug-carrier ratio. Compared with the pure drug, the solubilities of HPMC-cisapride solid dispersion are increased by 239.4% in SGF, 132.6% in water, and 117.9% in SIF. According to the in vitro drug release, the sustained release tablet prepared with HPMC-cisapride solid dispersion had a faster drug release than did that prepared with pure drug. The in vitro drug release profiles were found to comply with Higuchi's rule. Conclusion The in vitro drug release of the sustained release tablet made by HPMC-cisapride solid dispersion is improved owing to the increased drug solubility.

X-ray powder diffraction data for mosapride dihydrogen citrate dihydrate

Crystal Structure of 2-(1-benzyl-3-phenyl-1h-pyrazol-5-yl)-5-(4-nitrobenzylthio)-1,3,4-oxadiazole, C25H19N5O3S

Synthesis and Crystal Structure Characterization of (1R,2R,3R,5S)-3-(3-chlorophenyl)-1-hydroxy-2-methyl-6-phenyl-8-oxa-6-azabicyclo[3.2.1]octan-7-one

Comparison and Determination of the Content of Mosapride Citrate by Different qNMR Methods

Crystal Structure and X-ray Powder Diffraction Data for Two Solid-State Forms of Topiroxostat

X-ray Powder Diffraction Data for Bisacodyl, C22H19NO4

1H and 13C NMR Assignments for Mosapride

Hydrogen bonding patterns and C-H...π interactions in the structure of the antiparkinsonian drug (R)-rasagiline mesylate determined using laboratory and synchrotron X-ray powder diffraction data

[A Randomized Controlled Multi-center Clinical Trial on Mosapride in the Treatment of Functional Dyspepsia].

X-ray Powder Diffraction Data for 5-Chloro-n-(4-(5,6-dihydro-3-(4-morpholinyl)-2-oxo-1(2h)-pyridinyl)phenyl)-pentanamide, C20H26ClN3O3

An Updated Structure of Oxybutynin Hydrochloride

Development of a novel bi-coated combination capsule containing mosapride and probiotics for irritable bowel syndrome

Dissolution Improvement of Cisapride by Solid Dispersion with HPMC

Crystal structure of ractopamine hydrochloride, C 18 H 24 NO 3 Cl

Unlocking the secrets of doxepin hydrochloride's crystal structure: Insights from high-quality powder diffraction analysis

Crystal structure and X-ray powder diffraction data for Lumateperone tosylate

Oral Bioavailability Enhancement of Poorly Soluble Drug by Amorphous Solid Dispersion Using Sucrose Acetate Isobutyrate

Powder X-ray Diffraction of 1-(4-aminophenyl)-5,6-dihydro-3-(4-morpholinyl)-2(1h)-pyridinone, C15H19N3O2

Microelectron Diffraction Reveals Contamination of Polymorphs by Structure Analysis of Microscale Crystals in a Novel Pharmaceutical Cocrystal

Synthesis, Crystal Structure, Dft Studies and Biological Activity of A Novel Schiff Base Containing Triazolo [4,3-A]pyridine Moiety

Crystal Structure of (S)-4-(2-(4-(2-acetyl-5-chlorophenyl)-3-methoxy-6-oxopyridazin-1(6h)-yl)-3-phenylpropanamido)benzoic Acid Monohydrate, C29H26ClN3O7